MedTrace Logo

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

NCT06231693 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2025-05-08

No results posted yet for this study

Summary

A national, multicenter, retrospective, observational study (Real-World Evidence-RWE) aimed to assess the efficacy of Trastuzumab-deruxtecan (T-DXd) in patients with triple-negative (RE\<10%) metastatic HER2-Low breast cancer.

Conditions

Interventions

DRUG

Trastuzumab deruxtecan

Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting

Sponsors & Collaborators

  • Hospital Israelita Albert Einstein

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Italo Fernandes, MD · Hospital Israelita Albert Einstein

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-04
Primary Completion
2024-03-26
Completion
2024-03-26
FDA Drug
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06231693 on ClinicalTrials.gov